2080 Century Park E #803 Los Angeles, CA 90067
M-F, 8:30 AM to 5:00 PM
Explore the mechanism of action and development of chimeric antigen receptor (CAR) T-cell therapy for leukemia and lymphoma. Learn about the engineering of CAR T-cells to recognize and target specific antigens on cancer cells, leading to potent antitumor immune responses.
Discover the clinical efficacy and safety profile of CAR T-cell therapy in the treatment of leukemia and lymphoma. Explore pivotal clinical trials and real-world evidence demonstrating high response rates, durable remissions, and manageable adverse events associated with CAR T-cell therapy.
Discuss the criteria for patient selection and pre-treatment evaluation for CAR T-cell therapy. Explore strategies for managing cytokine release syndrome (CRS) and neurotoxicity, common side effects of CAR T-cell therapy, and optimizing patient outcomes through supportive care measures.
Address the challenges and limitations of CAR T-cell therapy, including antigen escape, tumor heterogeneity, and treatment resistance. Explore ongoing research efforts and innovative strategies for overcoming these barriers and enhancing the efficacy of CAR T-cell therapy in leukemia and lymphoma.
Explore the potential of combination approaches, including CAR T-cell therapy with other immunotherapies, targeted therapies, and chemotherapy, in leukemia and lymphoma treatment. Gain insights into future directions and emerging trends in CAR T-cell therapy research, such as off-the-shelf CAR T-cells and gene editing technologies.
Discuss the economic implications and access challenges associated with CAR T-cell therapy, including cost-effectiveness, reimbursement issues, and disparities in access to innovative cancer treatments. Explore efforts to improve affordability and accessibility of CAR T-cell therapy for all patients in need.
